Project

Development and Testing of an Innovative Technology for the Production of Specific Antibodies and a Device for Rapid Virus Diagnostics, Including SARS-CoV-2, Ready for Implementation in Diagnostics, Therapy, and Prevention in Epidemiological Threat Situations – FiBioMed

Project co-financed by the European Union from the European Regional Development Fund under the Smart Growth Operational Programme 2014–2020.
Project implemented under the National Centre for Research and Development call: 5/1.1.1/2020 – Fast Track – Coronaviruses

Project number: POIR.01.01.01-00-1188/20
Priority axis: Support for conducting R&D activities by enterprises
Measure: R&D projects of enterprises
Sub-measure: Industrial research and development works carried out by enterprises
Project value: 12,327,736.88 PLN,
PORT share: 1,284,734.38 PLN
Total funding: PLN 10,046,456.53, PORT share: 1,284,734.38 PLN
Project implementation period: 01/01/2021 – 30/09/2023
Project leader: Dr. Tomasz Lipiński

Project implemented in a consortium:
FIBIOMED Spółka z Ograniczoną Odpowiedzialnością – Consortium Leader
Łukasiewicz Research Network – PORT Polish Center for Technology Development

The aim of the project is to develop, test, and implement an innovative device for high-throughput, partially automated analysis of samples for the presence of the SARS-CoV-2 virus, which can be easily and rapidly adapted for the analysis of other pathogens or diagnostic markers. The device will be based on fiber-optic technology developed by SDS Optic. The signal measured by the device is generated as a result of molecular interactions on the surface of the probe, in this case between viral protein antigens and antibodies recognizing them, immobilized on the probe.

A key feature of the new system will be its high throughput (the ability to measure 96 samples simultaneously), rapid measurement time, and the capability to analyze more than one viral protein. It will also be possible to analyze antibodies against SARS-CoV-2 antigens in patient serum, providing a more comprehensive picture of the course of infection than other available methods. The Bioengineering Research Group will develop and produce the biological components necessary for probe preparation (viral antigens and antibodies), as well as develop a system using functionalized nanoparticles to increase detection sensitivity.

[ninja_form id=17]

This will close in 0 seconds

This will close in 0 seconds